Form 4: Climb Bio Director Judith Dunn Granted 40,000 Stock Options

Climb Bio, Inc. Director Judith Dunn was granted 40,000 stock options with an exercise price of $1.29, vesting by June 2026 or the next annual meeting.

Summary

• Judith Dunn, a Director of Climb Bio, Inc. (CLYM), was granted 40,000 stock options.
• The transaction date for the option grant was June 4, 2025.
• Each stock option has an exercise price of $1.29.
• The options will vest on the earlier of June 4, 2026, or the date immediately prior to the next annual meeting of stockholders, contingent on Ms. Dunn's continued service.
• The options have an expiration date of June 3, 2035.
• Following this transaction, Judith Dunn beneficially owns 40,000 derivative securities (stock options) directly.
• A Power of Attorney was executed by Judith Dunn on June 3, 2025, appointing Chandra Adams, Aoife Brennan, and Emily Pimblett as attorneys-in-fact for SEC Section 16 filings.

Sentiment

Score: 7

Explanation: The document reports a standard compensation event (stock option grant) for a director, which is generally positive for governance and alignment, but does not contain significant new financial or operational information to dramatically shift sentiment.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The options are subject to a vesting schedule, indicating a future commitment from the director to continued service with the company.

Industry Context

The granting of stock options to directors is a common practice across various industries, particularly in biotechnology and growth-oriented companies, to attract and retain talent and align their interests with shareholder value creation.

Corporate Governance

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with shareholder value creation, as the options gain value if the stock price increases.
• Employees: While not directly impacting all employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The stock options will vest on the earlier of June 4, 2026, or the date immediately prior to the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Climb Bio, CLYM, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Vesting